Key Facts Surrounding This News Item
- GNPX had returned 0.00% year-to-date leading up to today’s news, versus a -2.24% return from the benchmark S&P 500 during the same period.
More Info About Genprex, Inc. (GNPX)
Genprex, Inc., a clinical stage gene therapy company, develops drugs to treat cancer. Its lead product candidate is Oncoprex, an active anti-cancer agent that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). It also conducts preclinical research for developing Oncoprex to be administered with immunotherapies in NSCLC; and research into other tumor suppressor genes associated with chromosome. The company was founded in 2009 and is based in Austin, Texas. View our full GNPX ticker page with ratings, news, and more.